Detecting differential allelic expression using high-resolution melting curve analysis: application to the breast cancer susceptibility gene CHEK2 by Nguyen-Dumont, Tú et al.
RESEARCH ARTICLE Open Access
Detecting differential allelic expression using
high-resolution melting curve analysis:
application to the breast cancer susceptibility
gene CHEK2
Tú Nguyen-Dumont





Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab)
3,
Olga Sinilnikova
4, Florence Le Calvez-Kelm
1, Melissa C Southey
5, Sean V Tavtigian
6 and Fabienne Lesueur
1*
Abstract
Background: The gene CHEK2 encodes a checkpoint kinase playing a key role in the DNA damage pathway.
Though CHEK2 has been identified as an intermediate breast cancer susceptibility gene, only a small proportion of
high-risk families have been explained by genetic variants located in its coding region. Alteration in gene
expression regulation provides a potential mechanism for generating disease susceptibility. The detection of
differential allelic expression (DAE) represents a sensitive assay to direct the search for a functional sequence
variant within the transcriptional regulatory elements of a candidate gene. We aimed to assess whether CHEK2 was
subject to DAE in lymphoblastoid cell lines (LCLs) from high-risk breast cancer patients for whom no mutation in
BRCA1 or BRCA2 had been identified.
Methods: We implemented an assay based on high-resolution melting (HRM) curve analysis and developed an
analysis tool for DAE assessment.
Results: We observed allelic expression imbalance in 4 of the 41 LCLs examined. All four were carriers of the
truncating mutation 1100delC. We confirmed previous findings that this mutation induces non-sense mediated
mRNA decay. In our series, we ruled out the possibility of a functional sequence variant located in the promoter
region or in a regulatory element of CHEK2 that would lead to DAE in the transcriptional regulatory milieu of freely
proliferating LCLs.
Conclusions: Our results support that HRM is a sensitive and accurate method for DAE assessment. This approach
would be of great interest for high-throughput mutation screening projects aiming to identify genes carrying
functional regulatory polymorphisms.
Background
The CHEK2 gene (cell cycle checkpoint kinase 2) is a
multiorgan tumour susceptibility gene involved in the
maintenance of genomic stability. CHEK2 functions
downstream of ATM (Ataxia-telangiectasia mutated) to
phosphorylate several substrates, including TP53
(Tumour protein p53), Cdc25C (Cell division cycle 25C)
and BRCA1 (Breast cancer 1, early onset), leading to cell
cycle arrest, activation of DNA repair or apoptosis in
response to DNA double-stranded breaks. Since CHEK2
plays a key role in the DNA damage pathway, loss of
function of the protein may allow cells to evade normal
cell cycle checkpoints, ultimately leading to tumour
initiation or progression. The CHEK2*1100delC dele-
tion, falling in the kinase domain of the protein, has
been widely studied for its contribution to inherited
breast cancer susceptibility [1]. This mutation induces a
premature stop codon in exon 10, and causes the trun-
cation of the protein at codon 381 thus abrogating its
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fers between ethnic populations, and is higher in the
North of Europe and low or absent in other countries
[2].
The CHEK2-Breast Cancer Consortium reported a fre-
quency of 5.1% for the CHEK2*1100delC variant in
familial breast cancer cases who tested negative for
BRCA1 and BRCA2 (Breast cancer 2, early onset) muta-
tions, as opposed to 1.1% of carriers in the control
population [3]. This intermediate-risk breast cancer sus-
ceptibility allele almost triples the risk of developing the
disease in unselected breast cancer cases (OR = 2.34;
95% CI[1.72 - 3.20]) [4]. Other founder mutations in
CHEK2 have been associated with an increased risk of
cancer [5]. Though first discovered in breast cancer
patients, CHEK2 mutations have since been reported to
predispose to a range of cancer types, including ovarian,
prostate, kidney and colorectal cancers [6], supporting
the hypothesis that CHEK2 is a multiorgan cancer sus-
ceptibility gene [5].
As part of an international breast cancer genetics
study aiming to investigate candidate genes conferring
an intermediate-risk of breast cancer, we mutation
screened the coding exons and the adjacent proximal
introns of CHEK2 in 1415 cases and 1204 controls. The
main goal of this study was to evaluate and to compare
the role of truncating mutations, splice junction muta-
tions and rare missense substitutions in breast cancer
susceptibility [7]. In order to fully assess the contribu-
tion of CHEK2 in breast cancer susceptibility, we aimed
to test whether the gene was subject to differential alle-
lic expression (DAE). In such a case, it would be worth
extending variant discovery efforts from the coding
sequence of the gene to known or predicted regulatory
regions to search for causal variants. Indeed, phenotypic
variation may be influenced by sequence variations in
genes by alterations in the quality or in the quantity of
the encoded proteins [8]. These changes are transmitted
from the gene to the protein in the guise of modifica-
tions of the sequence or the abundance of mRNA. From
this perspective, it can be hypothesized that gene
expression regulation may be the underlying explanation
for a proportion of cancer that have not been resolved
yet by mutation screening of coding regions in currently
known cancer predisposition genes.
Allelic imbalance was first described in parental
imprinting and X-chromosome inactivation but it is
becoming clear that cis-acting variations in gene expres-
sion occur commonly in the human genome, playing a
key-role in human phenotypic variability [9-11]. Charac-
terization of the effect of cis-acting polymorphisms in
regulatory regions is a great challenge due to the diffi-
culty to locate these regions. In addition, regulatory var-
iants are not robustly detected by sequence analysis
since SNP identification by screening regulatory regions
does not consistently allow prediction of the effect of
observed SNPs on gene expression. Thus, knowledge of
the effect of genetic variants affecting mRNA transcrip-
tion is very limited. One possible approach to address
this issue is the examination of disruption/alteration of
gene expression level. The most sensitive test for this
phenomenon is to carry a careful survey of whether two
alleles of a gene are equally expressed. This approach
has been used in studies aiming at identifying functional
cis-variants that can have a role in susceptibility to
breast [12,13] and colorectal cancer [14,15]. In some
cases, observation of DAE will be explained by a trun-
cating mutation resulting in non-sense mediated mRNA
decay (NMD) or by a splice junction mutation resulting
in an unstable transcript. However, DAE can also be the
signature of a heterozygous carriage of a regulatory var-
iant [16] or of an epigenetic event (methylation) [17].
In this study, we used a high-resolution melting
(HRM) analysis approach to perform allele-specific
expression measurement in CHEK2.A si nc u r r e n t l y
used methods for investigating DAE, this approach is
applied to individual subjects who are heterozygous for
an exonic marker SNP, specifically targeted by a labelled
probe, called SimpleProbe [18,19]. Data acquisition on
HRM instruments consists of monitoring changes in the
fluorescence intensity of the probe, as it dissociates
from the two allelic templates, while the probe-target
duplexes are continuously heated. We have already
reported the use of this methodology to compare the
relative abundance of allelic transcripts in a study inves-
tigating mRNA degradation due to NMD in BRCA2
[19], and in a group of selected genes involved in the
cellular response to the cytotoxic agent cytarabine [20].
In these studies, DAE analysis was limited by the single-
capillary throughput of the HRM device used, the HR-
1™ instrument, and allelic imbalance was quantified
manually. Here, we report additional experiments and
testing, as well as up-scaling possibilities with a high-
throughput HRM device, the LightScanner
® instrument
that uses a 384-well plate format. To improve the analy-
sis of allelic expression, an analysis tool was developed
using R in order to process data acquired with HRM
commercialized software. Our script provides allelic
imbalance estimates and subsequent statistical calcula-
tions that are required to assess DAE.
Methods
Lymphoblastoid cell lines
We used a total of 89 lymphoblastoid cell lines (LCLs)
derived from breast cancer patients, who were consid-
ered to be at high risk of carrying a genetic predisposi-
tion to cancer due to an early age at onset and/or family
history, and for whom no mutation in BRCA1 or BRCA2
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obtained from Creighton University School of Medicine
(Omaha, NE, USA, 33 familial cases), Centre Léon
Bérard (CLB, Lyon, France, 21 patients diagnosed below
age 50) and the Kathleen Cuningham Consortium for
Research into Familial Aspects of Breast Cancer (kCon-
Fab, Melbourne, Australia, 35 familial cases). LCLs were
established by Epstein-Barr virus immortalization of
patients’ blood lymphocytes. Cells were maintained in
RPMI 1640 medium (Invitrogen, Cergy-Pontoise,
France) supplemented with 20% fetal calf serum (VWR,
Fontenay-sous-bois, France), 0.4% fungizon (Qiagen,
Courtaboeuf, France) and 1% penicilin-streptomycin
(Invitrogen), in 5% CO2 incubator at 37°C with 95%
humidity. For NMD inhibition, LCLs were treated for 6
hours with 100 μM puromycin (Sigma Aldrich, St
Quentin Fallavier, France).
DNA samples
Genomic DNAs and total RNAs were extracted from
LCLs using Puregene DNA isolation kit (Qiagen) and
NucleoSpin RNA II kit (Machery Nagel, Hoerdt,
France), respectively. Integrity of RNA was controlled
using the BioAnalyzer and RNA NanoChip II kit (Agi-
lent, Massy, France) according to the manufacturer’s
instructions. RNAs harbouring an RNA integrity num-
ber (RIN) ≥ 8 were selected for further analysis [21].
Whenever the quality threshold was not reached, a new
RNA extraction was performed so that all the RNAs
used in this study had a minimum RIN of 8. Comple-
mentary DNA (cDNA) synthesis was performed from 1
μg total RNA using SuperScript™ III First Strand
Synthesis System for RT-PCR (Invitrogen) with oligo
(dT) primers, according to the manufacturer’s
instructions.
Mutation screening
The 89 subjects included in this study were drawn from a
large-scale case-control mutation screening study invol-
ving 1415 cases and 1204 controls, that has been described
elsewhere [22,23]. CHEK2*1100delC carriers were all con-
firmed by direct sequencing on genomic DNA (For muta-
tion screening results, see Additional file 1).
PCR amplification for DAE assessment
DAE was assessed in four replicates of primary PCR
(PCR1), both with cDNA, cDNA from puromycin-trea-
ted LCL, and genomic DNA (For primers and probes,
see Additional file 2). PCR1 contained 2 μlt e m p l a t e
DNA in 1× PCR Buffer, 1.5 mM MgCl2, 0.13 mM
dNTP, 0.2 μM forward and reverse primers specific to
genomic DNA or cDNA, and 0.05 Units Platinum Taq
Polymerase (Invitrogen), in a final volume of 8 μl. The
temperature cycling protocol was: 94°C for 3 minutes;
30 cycles at 94°C for 30 seconds, 62°C for 45 seconds
and 72°C for 30 seconds; and finally 72°C for 5 minutes.
To reduce competitive binding of the probe and the
complementary strand during the melting curve analysis,
the secondary PCR (PCR2) was carried out asymmetri-
cally, with the primer generating the target strand at a
5-fold higher concentration (0.5 μM) than the primer
for the other strand (0.1 μM). In addition, PCR2 con-
tained 2 μl of 1:15 diluted in TE
-4 PCR1 products com-
bined with 0.9× Buffer, 1.38 mM MgCl2, 0.12 mM each
dNTP, 0.5 μM SimpleProbe (Tib Molbiol, Berlin, Ger-
many) and 0.4 Units of Taq Platinum Polymerase in a
final volume of 6 μl. Clear oil (Avatech) saturated with
Tween 80 (Sigma Aldrich) was used to overlay PCR
reactions. The temperature cycling protocol was the
same as above, except that 45 cycles were performed.
DAE analyses were performed in batches of 96 samples,
corresponding to 4 replicates of genomic DNA, 4 repli-
cates of cDNA and 4 replicates of puromycin-treated
cDNA derived from 8 different LCLs.
High-resolution melting analysis
PCR product melting curves were obtained from the
HR-1™ and the LightScanner
® instruments by melting
from 35°C to 75°C. Data were obtained with the sup-
plied software (HR-1™ v1.5 and LightScanner
® Software
v2.0, respectively), and then exported to an analysis tool
that we developed in R, a programming language and
software environment for statistical computing and gra-
phics http://cran.r-project.org. R scripts were developed
in order to retrieve the data, to apply the Savitsky-Golay
filter to smooth the derivative melting curves and to cal-
culate the peak heights. For each sample, ratios were
measured from 4 PCR-replicates and the mean ratio was
calculated across all replicate samples. The R scripts are
available on http://sourceforge.net/projects/hrmdae. The
level of allelic imbalance for each individual was deter-
mined from the difference between the log of the signal
ratio in cDNA and the corresponding log ratio in geno-
mic DNA. Statistical significance for the allelic imbal-
ance was calculated using Student’s t-test. Criteria for
DAE were the following: i) the point estimate of the dif-
ference between genomic DNA and cDNA ratios should
be greater than 20%; ii) the Student’s t-test p-value
should be ≤ 0.05, and iii) the 95% confidence interval of
the point estimate should not include 0 [14,19,20,24].
Results
Genotyping of CHEK2 exonic SNPs
The main goal of the initial case-control mutation-
screening project was to identify rare, potentially patho-
genic genetic variants within the coding sequence and
t h ep r o x i m a li n t r o n i cs p l i c ec o n s e n s u ss e q u e n c e s
of CHEK2. This mutation screening simultaneously
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every subject enrolled in the molecular epidemiology
study. For 89 of the breast cancer patients investigated,
LCLs were available to conduct DAE analysis.
In order to make a differential measurement of the
level of expression of the two alleles of a gene for a
given patient, one must be able to distinguish between
the alleles. We used the two most common exonic
SNPs that were identified during the mutation screening
process, namely rs2236142 and rs2236141, and only the
cell lines that are heterozygote for at least one of the
two SNPs were selected for further analysis. These two
markers are reported to be common in the dbSNP data-
base (Minor allele frequency of 49.2% and 25.4% in Eur-
opean populations, respectively). Thirty-two out of 89
cell lines were heterozygotes for rs2236142 and 17 out
of 89 were heterozygotes for rs2236141 (see Additional
Table 1). Eight individuals were double heterozygotes.
Evaluation of the HRM method to detect DAE
This technique relies on the distinction between the two
alleles in heterozygous individuals using differences in
melting temperature (Tm) with a derivative fluorescent
signal correlated to the relative abundance of each tran-
script. We first verified that HRM could distinguish
between the two alleles of each SNP in our experimental
conditions, by assaying genomic DNA and cDNA from
all three genotypes. Analysis of the melting curves of
the homozygous samples showed a transition at a Tm
specific to each allele (Figure 1). Melting transitions
were converted into peaks on the derivative plot. Het-
erozygous samples presented transitions and peaks
corresponding to each allele at both Tm. A no-template
control was taken as baseline to subtract local back-
ground value to the fluorescence intensity of the
samples.
To examine the feasibility of detecting DAE by melt-
ing curve analysis, we created a range of melting curves
associated with known allelic imbalance. Using homozy-
gous genomic DNAs, we produced bi-allelic templates
with increasing minor allele:major allele proportions
(9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9).
Allelic (im)balance was observed as the ratio of the
peak heights of the fluorescence signal. As expected, the
melting profiles of the mixtures of opposite homozy-
gotes reflected the relative contribution of each allele
to the total mixture (Figure 2A). For both SNPs we
observed good correlations between allelic imbalance
and peak height ratio measurements. For rs2236142,
R
2 = 0.974 on HR-1™ and R
2 = 0.963 on LightScanner
®
(Figure 2B); for rs2236141, R
2 = 0.973 on HR-1™ and
R
2 = 0.963 on LightScanner
® (data not shown). The
mixing experiments showed that the measured allelic
ratios varied in a linear relationship with the dilution
ratios. Altogether, these results show that HRM is able
to accurately detect different extents of DAE.
Assessment of DAE for CHEK2 in LCLs from breast cancer
patients
Mutation screening of the 89 LCLs identified four car-
riers of the CHEK2*1100delC mutation (see Additional
file 1). This mutation induces a premature termination
codon and has been reported to trigger the NMD path-
way [25,26], which leads to the specific degradation of
m R N A sb e a r i n gs u c hd e l e t e r i o u sm u t a t i o n[ 2 7 ] .I n
order to distinguish DAE that would be caused by
NMD from DAE that would be caused by a regulatory
variant altering the level of expression of the transcript,
cDNA was derived from LCLs treated and untreated
with puromycin, from each individual.
We performed quantitative measurements on genomic
DNA and on both types of cDNA. Genomic DNA
served as an internal control and provided the expected
peak heights ratio value for a 1:1 allelic ratio, thereby
controlling for any bias in the binding of the fluorescent
probe to the two alleles. Because of differences in fluor-
escence yield, measured peak heights ratios differed
from unity when genomic DNAs were assessed. How-
ever, the melting profiles of genomic DNA were in
accordance with what was expected from the mixing
experiment.
The first series of analysis using the SNP rs2236142 as
marker included 32 heterozygous individuals for this
coding SNP. The statistical threshold for DAE was
reached in four individuals (Figure 3). Mutation screen-
ing results indicated that these four patients carried the
CHEK2*1100delC mutation (see Additional file 1).
Observed levels of DAE varied from 37% to 60%, reveal-
ing a substantial expression imbalance of an order likely
to have biological importance. NMD inhibitory treat-
ment on these four LCLs showed melting curves profiles
tending towards the genomic curve profile, which is the
reference for a 1:1 allelic ratio (Figure 4A). This con-
firms previous findings that the CHEK2*1100delC muta-
tion leads to allele-specific degradation by triggering the
NMD pathway [3]. None of the 28 other individuals of
Table 1 Comparison of the duration of the DAE analysis
between the HR-1™ and the LightScanner
® instruments,
for 96 samples
DAE step HR-1™ instrument LightScanner
® instrument
PCRs Same duration Same duration
Data acquisition 2 days 12 minutes
Data analysis 1 full day 15 minutes
The HR-1™ instrument can only analyze a single sample per run making data
analysis time consuming. The LightScanner
® instrument, with its 384-well
plate format, is of greater practical efficiency. Data analysis was performed
using an analysis tool that we developed.
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our statistical criteria (Figure 4-B). The second series of
analysis used SNP rs2236141 as marker and included 17
heterozygous individuals for this coding SNP. Eight of
them were also heterozygous for SNP rs2236142 and
had already tested negative for DAE with the first
marker. The statistical threshold for DAE was not
reached in any of the remaining 9 samples (Figure 3).
Discussion
Our work supports the high sensitivity of HRM for the
detection and quantification of DAE. We have shown
Figure 1 Principle of high-resolution melting curve analysis (HRM) for detection of allelic expression imbalance. A single labelled
fluorescent probe is designed with complete complementarity to one allele of the exonic SNP chosen as marker, while mismatching the other
allele. Following an asymmetric PCR reaction in presence of the probe, HRM analysis allows the alleles in heterozygous individuals to be
distinguished by differences in their melting temperatures (Tm), with a fluorescent signal correlated to the relative abundance of each transcript.
The Allele 2/Allele 1 ratio is calculated as h2/h1.
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in LCLs carrying a non-sense mutation in CHEK2.
Although no DAE was observed in the patients who do
not carry the 1100delC mutation, the series investigated
here was limited, and we cannot rule out that cis-regula-
tory variants in CHEK2 may lead to DAE in a tissue
specific manner [24]. However, this later hypothesis
could not be tested since no breast tissue was available
from these patients.
The approach used in our study relies on subjects who
are heterozygous for a coding SNP and allows relative
quantification of allelic transcripts. This methodology
has major advantages over more conventional methods
for investigating DAE based on the comparison of gene
expression between individuals as discussed elsewhere
[8,10,20]. Since they come from the same tissue sample
and have therefore been subjected to the same environ-
mental influences (such as genetic trans-acting factors
and experimental exposures, including mRNA degrada-
tion) both alleles should be equally expressed in the
absence of cis-acting sequence variation or epigenetic
effects affecting the expression of the target mRNA.
Thus, the strength of this approach is that each allele
acts as an internal control for confounding factors, dis-
closing cis-variation effects without being confounded
by any trans-variation effects.
Here, we report a complete solution for HRM analysis
that can be used on both the HR-1™ (1 single capillary)
Figure 2 Mixing experiment to assess efficiency of HRM for detection of differential allelic expression. (A) SimpleProbe
® melting curves
generated on the LightScanner
® instrument from mixing series of opposite homozygous genomic DNAs for the marker SNP rs2236142 in CHEK2.
Mixing ratios are indicated on the figure (G allele: C allele ratio). (B) The determination coefficient (R2) between the expected and the observed
allelic ratios was 0.963. Each value corresponds to the mean value of 4 replicate measurements.
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® (384-well plate format) instruments,
with the format depending on the required throughput.
Access to DAE assessment technology can be cost pro-
hibitive for many laboratories. HRM provides a good
alternative when compared to methodologies based for
instance, on the use of capillary electrophoresis for sin-
gle-base extension assays, such as SnapShot assays [11],
allele-specific quantitative real-time PCR [12] and
microarray platform [9]. Advantages offered by HRM
analysis include its rapidity, cost-effectiveness and secur-
ity due to its closed-tube nature. Though the HR-1™ is
reported to provide a better accuracy [28], both instru-
ments performed well to identify the 4 carriers of the
CHEK2*1100delC variant showing DAE in the absence
of puromycin treatment in our study. However, given
the number of samples to test, analysis with the HR-1™
instrument ended up being much more time consuming
(Table 1). The results obtained with the LightScanner
®
instrument showed that this methodology can be
applied in larger-scale studies, provided that LCL mate-
rial is available, while maintaining high accuracy and
remaining cost-effective. Indeed, the protocol is rela-
tively inexpensive since it only requires standard PCR
reagents and a small amount of fluorescent probe.
The script we developed using R computing software
was made compatible with both instruments and greatly
reduces the time of analysis. Once HRM data are
acquired, the normalization of the curves, peak heights
measurements, ratios calculations and statistical analysis
are performed automatically within less than 15 minutes
for a set of 96 samples when using the LightScanner
®
instrument. The output consists in a summary table of
the peak heights, relative allelic ratios, and the Student’s
t-test values, as well as a plot on which DAE carriers are
highlighted. The script can also display other information
on demand, such as melting curve profiles which can be
displayed for each replicate or by average of 4 replicates
for each individual (see examples in Figure 3 and 4).
In DAE analysis by HRM, the peak heights obtained
from the melting curve reflect the relative abundance of
each allele’s transcript. The reproducibility and precision
of the assay are reasonable as seen in the small standard
deviations associated with the calculations. The accuracy
of the method was illustrated by the consistency of the
allelic expression estimates across multiple replicates
assay within the same individual sample. Genomic DNA
ratios varied within a very narrow range, showing the
excellent reproducibility and precision of the assay on
DNA derived from LCL. The intra-sample variation in
replicate analysis was higher for mRNA ratios than for
DNA ratios, possibly owing to RNA stability. In addi-
tion, at low copy numbers of mRNA, the stochastic dis-
tribution of the RNA templates may be a major source
of variation and hence affect the accuracy of DAE
Figure 3 R plot showing the DAE assay results for the 41 heterozygous individuals enrolled in the study. The level of DAE is calculated
by dividing the allelic ratio in cDNA by the corresponding ratio in genomic DNA (log cDNA-log gDNA). Statistical significance for DAE is
evaluated using Student’s t-test. Evidence for DAE is reached when i) the point estimate of the level of DAE (plotted on the horizontal axis) is
greater than 20%, ii) the Student’s t-test p-value (plotted on the vertical axis) is ≤ 0.05, and iii) the 95% confidence interval of the point estimate
(based on 4 replicate assays) does not include 0. Samples above the horizontal line and outside the hatched area reached the statistical
threshold for DAE. In our experiment, four samples met all criteria (Samples 2181, 2498, 2500 and 2666).
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instance [29].
I naD A Es t u d y ,t h em a i no ptimization issue is the
ability to select a subset of 2-3 marker SNPs so that as
many individuals as possible are heterozygous for at
least one of the markers. Subsets of individuals giving
the most heterozygotes at 2 loci should be chosen in
order to maximize redundancy, and to self-check for
error reduction. Unfortunately, in the present study, no
individual heterozygous for both SNPs showed evidence
of DAE. Detection of DAE in a candidate gene may be
indicative of the presence of a coding or regulatory var-
iant altering expression of the gene product. However,
DAE-based approaches can point out the presence of a
regulatory causative variant only if the subjects are
heterozygous for the causative variant (and of course for
the coding SNP serving as marker). In some situations,
the coding SNP used to distinguish both alleles may be
itself responsible for the observed DAE, or it can be in
linkage disequilibrium (LD) with it, i.e. on the same hap-
l o t y p e .I nt h ec a s eo fn oL Db e t w e e nt h em a r k e ra n d
the functional variant, it is still possible to map the
variant, as previously reported by others [30,31].
Conclusions
Allele-specific expression assays can be applied to iden-
tify genetic variants located in regions essential for gene
expression regulation or splicing. Thus, identification of
a list of genes for which DAE has been detected would
yield a considerable reduction of the amount of work,
Figure 4 Non-sense mediated mRNA decay causes differential allelic expression in CHEK2*1100delC carriers. Allelic ratio measurements
were performed on genomic DNA (gDNA), cDNA derived from LCLs in standard cell culture condition, and cDNA from LCLs treated with
puromycin, an NMD inhibiting agent. (A) For a carrier of the mutation, comparison of gDNA and cDNA melting profiles supports the existence of
DAE. Puromycin-cDNA profile resembles gDNA, supporting the role of NMD in the DAE observed in this individual. (B) The wild-type sample
shows similar profiles in all three situations. HRM profiles were generated with the R script.
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are most likely to harbour coding or regulatory variants
that may alter gene expression. The approach reported
here allows revealing the existence of regulatory varia-
tions without directly identifying or requiring prior
knowledge of specific cis-regulatory SNPs. DAE assays
can also highlight the existence of epigenetic factors
controlling gene expression [32].
Analysis of the relative allelic ratios of marker SNPs
circumvents the issue of confounding trans-acting fac-
tors. Any significant differences in these ratios support
the existence of DAE and hence, cis-acting polymorph-
isms determining gene expression. The primary goal of
this type of study is to identify sequence variants that
are likely to alter gene expression and gene product
function, and thereby influence susceptibility to breast
cancer. However, to demonstrate that some of these var-
iants actually show disease association, large-scale epide-
miological studies are required and may ultimately lead
towards the identification of causal genetic factors
responsible for susceptibility to disease. In the context
of such high-throughput studies, instead of LCLs, one
can use blood samples, a more accessible tissue than
breast. Identification and elucidation of rare intermedi-
ate-risk genetic variants associated with susceptibility to
cancer will contribute to a better understanding of the
aetiology of the disease.
Software availability
A copy of our R script code has been made available on
http://Sourceforge.net.
Project name: HRMdae project;
Project home page: http://sourceforge.net/projects/
hrmdae;
Operating system(s): Platform independent, R
environment;
Programming language: R v2, or above;
Licence: GPL v3;
Any restrictions to use by non-academics: None.
Additional material
Additional file 1: Mutation screening results for the 41 breast
cancer samples enrolled in the DAE study. Additional table showing
the mutation screening results for the 41 breast cancer samples enrolled
in the DAE study.
Additional file 2: Primers and probes used in the DAE study on the
CHEK2 gene. Additional table showing the primers and probes
sequences used to perform the DAE study.
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